• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢癌二次探查剖腹术后的腹腔内磷酸铬治疗

Intraperitoneal chromic phosphate therapy after second-look laparotomy for ovarian cancer.

作者信息

Varia M, Rosenman J, Venkatraman S, Askin F, Fowler W, Walton L, Halle J, Currie J

机构信息

Division of Radiation Oncology, University of North Carolina, Chapel Hill 27514.

出版信息

Cancer. 1988 Mar 1;61(5):919-27. doi: 10.1002/1097-0142(19880301)61:5<919::aid-cncr2820610511>3.0.co;2-p.

DOI:10.1002/1097-0142(19880301)61:5<919::aid-cncr2820610511>3.0.co;2-p
PMID:3338057
Abstract

Between 1973 and 1985, 118 patients in clinical remission after initial surgery and postoperative chemotherapy for epithelial ovarian carcinoma underwent second-look laparotomy at the University of North Carolina. No evidence of disease (NED) was found in 57 of these patients; 43 patients received 15 mCi of radioactive chromic phosphate (32P) suspension given intraperitoneally in the immediate postoperative period. In 29 other patients, only microscopic or minimal residual disease (nodules less than 2 cm in size) was found, seven received 32P alone, ten received 32P and further chemotherapy, and 12 received chemotherapy alone. The 4-year postsecond-look survival of the patients with NED at second-look was 89% for those receiving 32P and 67% for those who had not. The respective figures for patients with minimal residual disease at second-look are 59% versus 22%. Irrespective of treatment, a group at high risk for failure after negative second-look laparotomy has been identified; those with an initial International Federation of Gynecology and Obstetrics (FIGO) stage greater than I and histologic grade greater than 1. A comparison of our data with 18 previously published series, indicates that use of postsecond-look intraperitoneal 32P can improve the progression-free interval, and possibly overall survival, of patients with NED or minimal residual disease without adding significant complications.

摘要

1973年至1985年间,北卡罗来纳大学对118例上皮性卵巢癌患者进行了初次手术及术后化疗,处于临床缓解期的患者接受了二次剖腹探查术。其中57例患者未发现疾病证据(NED);43例患者在术后即刻接受了15毫居里放射性磷酸铬(32P)悬浮液腹腔注射。另外29例患者仅发现微小或最小残留病灶(结节大小小于2厘米),7例仅接受32P治疗,10例接受32P及进一步化疗,12例仅接受化疗。二次探查时NED患者中,接受32P治疗的患者4年生存率为89%,未接受32P治疗的患者为67%。二次探查时最小残留病灶患者的相应数字分别为59%和22%。无论接受何种治疗,已确定二次剖腹探查阴性后有高失败风险的一组患者;即初始国际妇产科联盟(FIGO)分期大于I期且组织学分级大于1级的患者。将我们的数据与之前发表的18个系列进行比较表明,二次探查后腹腔内使用32P可改善NED或最小残留病灶患者的无进展生存期,并可能改善总生存期,且不会增加明显并发症。

相似文献

1
Intraperitoneal chromic phosphate therapy after second-look laparotomy for ovarian cancer.卵巢癌二次探查剖腹术后的腹腔内磷酸铬治疗
Cancer. 1988 Mar 1;61(5):919-27. doi: 10.1002/1097-0142(19880301)61:5<919::aid-cncr2820610511>3.0.co;2-p.
2
Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group.
J Clin Oncol. 2003 Aug 1;21(15):2849-55. doi: 10.1200/JCO.2003.11.018.
3
32P following negative second-look laparotomy for epithelial ovarian cancer.上皮性卵巢癌二次探查阴性剖腹术后的32P治疗
Gynecol Oncol. 1993 Aug;50(2):141-6. doi: 10.1006/gyno.1993.1183.
4
Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging.腹膜内注射磷酸铬P 32作为手术分期后持续性卵巢癌的挽救治疗。
Am J Obstet Gynecol. 1987 May;156(5):1153-8. doi: 10.1016/0002-9378(87)90131-1.
5
Intraperitoneal P-32 is not an effective consolidation therapy after a negative second-look laparotomy for epithelial carcinoma of the ovary.对于卵巢上皮癌二次探查剖腹术结果为阴性的情况,腹腔内注射磷-32并非有效的巩固治疗方法。
Gynecol Oncol. 1992 Nov;47(2):146-9. doi: 10.1016/0090-8258(92)90098-4.
6
Ovarian carcinoma: adjuvant treatment with P-32.卵巢癌:P-32辅助治疗
Radiology. 1987 Oct;165(1):275-8. doi: 10.1148/radiology.165.1.3628782.
7
CA-125 levels after surgical exploration and radioactive chromic phosphate in ovarian cancer patients.卵巢癌患者手术探查及放射性磷酸铬治疗后的CA - 125水平。
Gynecol Oncol. 1996 Oct;63(1):85-8. doi: 10.1006/gyno.1996.0283.
8
Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits.
Gynecol Oncol. 1989 Mar;32(3):314-8. doi: 10.1016/0090-8258(89)90631-8.
9
Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging.对于未接受全面手术分期的早期卵巢癌患者,采用辅助性腹膜内磷酸铬治疗。
Cancer. 1991 Aug 15;68(4):725-9. doi: 10.1002/1097-0142(19910815)68:4<725::aid-cncr2820680410>3.0.co;2-1.
10
Use of P-32 in stage III epithelial carcinoma of the ovary.P-32在卵巢III期上皮癌中的应用。
Gynecol Oncol. 1994 Jul;54(1):35-9. doi: 10.1006/gyno.1994.1162.

引用本文的文献

1
Intraperitoneal chemotherapy for ovarian cancer.卵巢癌的腹腔内化疗
Curr Oncol Rep. 2003 Nov;5(6):447-53. doi: 10.1007/s11912-003-0004-z.
2
Results of ovary tumor treatment with abdominally administered (198)Au evaluated on the basis of long term follow up.
Pathol Oncol Res. 2002;8(1):54-7. doi: 10.1007/BF03033702.
3
Second-look laparotomy for epithelial ovarian cancer: a reappraisal.
Curr Oncol Rep. 2001 Jan;3(1):11-8. doi: 10.1007/s11912-001-0037-0.
4
Radionuclide therapy revisited.放射性核素治疗再探讨。
Eur J Nucl Med. 1991;18(6):408-31. doi: 10.1007/BF02258432.